Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

ImmunityBio's ANKTIVA Now Available To Patients Through Both Commercial And Government Insurance Programs, Also Announced Plans To Expand Its Bladder Cancer Program Globally, Notably In The European Union And India

Author: Benzinga Newsdesk | August 12, 2024 08:48am

 

ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval

  • Global expansion of commercial and clinical bladder cancer programs
    • Filing process initiated with European Medicines Agency (EMA) for regulatory approval of ANKTIVA in European Union countries
    • Global filing for BCG naïve trial initiated (QUILT-2.005) in India
  • ANKTIVA Non-Small Cell Lung Cancer (NSCLC) FDA meeting held in June 2024

 

ImmunityBio, Inc. ((IBRX), today announced significant progress in market access, making ANKTIVA® (nogapendekin alfa inbakicept-pmln) widely available to patients through both commercial and government insurance programs. The company also announced plans to expand its bladder cancer program globally, notably in the European Union and India.

Posted In: IBRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist